Aliases & Classifications for Drug Addiction

MalaCards integrated aliases for Drug Addiction:

Name: Drug Addiction 54 52
Polysubstance Abuse 52 69
Polysubstance Abuse, Susceptibility to 29
Drug Addiction, Susceptibility to 13
Drug Dependence 69

Classifications:



External Ids:

OMIM 54 606581

Summaries for Drug Addiction

MalaCards based summary : Drug Addiction, also known as polysubstance abuse, is related to hepatitis d and schizophrenia. An important gene associated with Drug Addiction is FAAH (Fatty Acid Amide Hydrolase), and among its related pathways/superpathways are Beta-Adrenergic Signaling and T cell receptor signaling pathway. The drugs Buprenorphine and Cocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Description from OMIM: 606581

Related Diseases for Drug Addiction

Diseases related to Drug Addiction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
id Related Disease Score Top Affiliating Genes
1 hepatitis d 29.5 COMT DRD2 DRD4
2 schizophrenia 28.4 COMT DRD1 DRD2 DRD4
3 substance dependence 11.1
4 placenta disease 10.5 DRD2 DRD4
5 antisocial personality disorder 10.4 DRD2 DRD4
6 contact dermatitis 10.4 DRD2 DRD4
7 eosinophilia-myalgia syndrome 10.4 DRD2 DRD4
8 rhinoscleroma 10.3 COMT DRD2
9 teebi kaurah syndrome 10.3 COMT DRD2
10 anosognosia 10.2 COMT DRD2
11 ulcerative colitis 10.2 COMT DRD2
12 pyromania 10.1 DRD1 DRD2 DRD4
13 tongue disease 10.1 COMT DRD2
14 hepatitis 10.1
15 autosomal dominant non-syndromic intellectual disability 10.1 CREB1 MAP2K2
16 hemorrhagic cystitis 10.0 COMT DRD2 DRD4
17 neuronitis 10.0
18 carotid stenosis 10.0 COMT DRD2 DRD4
19 cecal benign neoplasm 10.0 COMT DRD2 DRD4
20 colon mucinous adenocarcinoma 10.0 COMT DRD2 DRD4
21 radioulnar synostosis 10.0 MAP2K1 MAP2K2
22 personality disorder 10.0 COMT DRD2 DRD4
23 osteogenesis imperfecta, type ix 10.0 COMT DRD2 DRD4
24 brain meningioma 10.0 COMT DRD2
25 albinism, oculocutaneous, type v 10.0 COMT DRD2 DRD4
26 hepatitis c 9.9
27 obesity 9.9
28 primary angle-closure glaucoma 9.9 COMT DRD1
29 substance abuse 9.9
30 hepatopulmonary syndrome 9.9 COMT DRD1 DRD2
31 meningitis 9.8
32 mononeuritis multiplex 9.8
33 subdural empyema 9.8
34 bacterial meningitis 9.8
35 endocarditis 9.8
36 growth restriction, severe, with distinctive facies 9.8 MAP2K1 MAP2K2
37 bone fracture 9.8 COMT CREB1 DRD2
38 giant cell reparative granuloma 9.8 COMT FAAH
39 pathological gambling 9.8
40 cerebritis 9.8
41 melanoma 9.8
42 suppurative periapical periodontitis 9.7 CREB1 DRD2
43 attention deficit-hyperactivity disorder 9.7
44 miliary tuberculosis 9.7
45 tuberculosis 9.7
46 cocaine dependence 9.7
47 viral hepatitis 9.7
48 periodontitis 9.7
49 osteomyelitis 9.7
50 lung disease 9.7

Graphical network of the top 20 diseases related to Drug Addiction:



Diseases related to Drug Addiction

Symptoms & Phenotypes for Drug Addiction

Clinical features from OMIM:

606581

GenomeRNAi Phenotypes related to Drug Addiction according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.23 COMT DRD1 DRD2 DRD4 FAAH GPSM1

MGI Mouse Phenotypes related to Drug Addiction:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 DRD4 FAAH GPSM1 MAP2K2 COMT CREB1
2 homeostasis/metabolism MP:0005376 9.91 COMT CREB1 DRD1 DRD2 DRD4 FAAH
3 cardiovascular system MP:0005385 9.87 COMT CREB1 DRD1 DRD2 GPSM1 MAP2K1
4 nervous system MP:0003631 9.56 COMT CREB1 DRD1 DRD2 DRD4 FAAH
5 muscle MP:0005369 9.55 GPSM1 CREB1 DRD1 DRD2 FAAH
6 normal MP:0002873 9.1 CREB1 DRD1 DRD2 FAAH MAP2K1 MAP2K2

Drugs & Therapeutics for Drug Addiction

Drugs for Drug Addiction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 439)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
2
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2 137-58-6 3676
5
Ondansetron Approved Phase 4,Phase 2,Phase 3,Phase 1 99614-02-5 4595
6
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
7
Hydrocodone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 125-29-1 5284569
8
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
9
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
10
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 249296-44-4 5310966
11
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
12
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 561-27-3 5462328
13
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
14
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 465-65-6 5284596
15
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
16
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
17
Amphetamine Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2 300-62-9 5826 3007
18
Bupropion Approved Phase 4,Phase 2,Phase 3,Phase 1 34841-39-9, 34911-55-2 444
19
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
20
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 16590-41-3 5360515
21
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112111-43-0
22
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 537-46-2 10836
23
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
24
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
25
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
26
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
27
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
28
Aripiprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129722-12-9 60795
29
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
30
Phenobarbital Approved Phase 4 50-06-6 4763
31
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59729-33-8 2771
32
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
33
Clozapine Approved Phase 4 5786-21-0 2818
34
Dextroamphetamine Approved, Illicit Phase 4,Phase 1,Phase 2,Early Phase 1 51-64-9 5826
35
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
36
Acamprosate Approved, Investigational Phase 4,Phase 1,Phase 2 77337-76-9 71158
37
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
38
Tiagabine Approved Phase 4,Phase 2 115103-54-3 60648
39
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
40
Vortioxetine Approved Phase 4 508233-74-7 9966051
41
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
42
Progesterone Approved, Vet_approved Phase 4,Phase 1 57-83-0 5994
43
Pramipexole Approved, Investigational Phase 4,Phase 1 104632-26-0 59868 119570
44
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
45
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1 4205-90-7 2803
46
Benzocaine Approved Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
47
Pregabalin Approved, Illicit, Investigational Phase 4,Early Phase 1 148553-50-8 5486971
48
Sodium oxybate Approved Phase 4 502-85-2 5360545
49
Metformin Approved Phase 4 657-24-9 14219 4091
50
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693

Interventional clinical trials:

(show top 50) (show all 826)

id Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence Unknown status NCT01038414 Phase 4
3 Pharmacologic MRI in Cocaine Addiction Unknown status NCT01652378 Phase 4 ondansetron, lidocaine
4 Comparison of Tramacet Versus Percocet in Post Surgical Patients Unknown status NCT02361567 Phase 4 Tramacet;Percocet
5 Varenicline Adjunctive Treatment in Schizophrenia Unknown status NCT00492349 Phase 4 Varenicline;Placebo
6 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
7 Treatment of Hepatitis C in Psychiatric Patients Completed NCT00751426 Phase 4
8 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
9 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
10 Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
11 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
12 Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial Completed NCT01760967 Phase 4 Dexmedetomidine
13 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
14 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
15 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
16 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
17 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
18 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
19 Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy Completed NCT01980550 Phase 4 sublingual nicotine
20 The Whole Day First Grade Program Completed NCT00257088 Phase 4
21 Varenicline in Drug Treatment Completed NCT01286584 Phase 4 varenicline;placebo
22 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine Completed NCT00314340 Phase 4 ER Morphine;hydrocodone plus acetaminophen;placebo
23 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
24 Efficacy of Escitalopram in the Treatment of Internet Addiction Completed NCT00565422 Phase 4 Escitalopram
25 Preventing Depression Relapse With Mindfulness-Based Cognitive Therapy Completed NCT00183560 Phase 4 Antidepressants;Placebo plus clinical management
26 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Completed NCT02626494 Phase 4 N-Acetylcystein;Placebo
27 Switching Antipsychotics: Abrupt Discontinuation Versus Overlap Completed NCT02640300 Phase 4 Clozapine
28 Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts Completed NCT01023659 Phase 4 bupropion;varenicline
29 Omega-3 Supplementation to ADHD Medication in Children Completed NCT02204410 Phase 4 ADHD Medication
30 Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic Completed NCT00381043 Phase 4 Acamprosate (Campral)
31 Effectiveness of Varenicline: Testing Individual Differences Completed NCT01228175 Phase 4 Placebo;Varenicline
32 STOP Study: Effectiveness of Zyban in a Clinical Population Completed NCT01015170 Phase 4 bupropion HCl
33 Hepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing Completed NCT00427206 Phase 4 acetaminophen (4g/day);placebo
34 Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia Completed NCT01850953 Phase 4 Varenicline;Placebo
35 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4 quetiapine
36 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
37 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
38 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
39 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
40 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
41 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
42 Effect of Behavioral Training on Physiological Responses to Smoking Cues, Affect and Cortisol Completed NCT01362101 Phase 4
43 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
44 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4 methadone;buprenorphine / methadone sequence
45 Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction Completed NCT00174850 Phase 4 Gaitril
46 Acamprosate: Genes Associated With Response Completed NCT00662571 Phase 4 acamprosate
47 Smoking Relapse Prevention in Schizophrenia Completed NCT00320697 Phase 4 bupropion + nicotine patch + nicotine gum or lozenges;Placebo pill + placebo patch
48 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
49 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4 Modafinil;Placebo
50 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4 Carbamazepine

Search NIH Clinical Center for Drug Addiction

Genetic Tests for Drug Addiction

Genetic tests related to Drug Addiction:

id Genetic test Affiliating Genes
1 Polysubstance Abuse, Susceptibility to 29

Anatomical Context for Drug Addiction

MalaCards organs/tissues related to Drug Addiction:

39
Brain, Testes, Cortex, Bone, Prefrontal Cortex, Breast, Amygdala

Publications for Drug Addiction

Articles related to Drug Addiction:

(show top 50) (show all 650)
id Title Authors Year
1
Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug. ( 28666892 )
2017
2
Age and impulsive behavior in drug addiction: A review of past research and future directions. ( 28778737 )
2017
3
The Role of NFkB in Drug Addiction: Beyond Inflammation. ( 28043969 )
2017
4
Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma. ( 28923912 )
2017
5
Ventral striatal regulation of CREM mediates impulsive action and drug addiction vulnerability. ( 28439100 )
2017
6
Modeling the development of drug addiction in male and female animals. ( 28624586 )
2017
7
Drug addiction and diabetes: South Asian action. ( 28585604 )
2017
8
Drug Addiction and DNA Modifications. ( 28523543 )
2017
9
Reward Prediction Errors in Drug Addiction and Parkinson's Disease: from Neurophysiology to Neuroimaging. ( 28417291 )
2017
10
Isolated native tricuspid valve endocarditis due to group A I^-hemolytic Streptococcus without drug addiction. ( 28746146 )
2017
11
Chinese Herbal Medicine for the Treatment of Drug Addiction. ( 28807162 )
2017
12
Commentary on Baghaie et al. (2017): Out of the shadows, into the limelight-sobering salience of meta-analysis of chronic periodontitis in drug addiction. ( 28378333 )
2017
13
Is biological aging accelerated in drug addiction? ( 27774503 )
2017
14
MicroRNAs regulate synaptic plasticity underlying drug addiction. ( 28873276 )
2017
15
Insights from Preclinical Choice Models on Treating Drug Addiction. ( 27916279 )
2017
16
Public Stigma Toward People With Drug Addiction: A Factorial Survey. ( 28499109 )
2017
17
G Protein-Gated Potassium Channels: A Link to Drug Addiction. ( 28188005 )
2017
18
Sepsis and persisting neutropenia in a drug addict. ( 28052478 )
2017
19
Role of Dopamine Signaling in Drug Addiction. ( 28474551 )
2017
20
Adverse effects of subcutaneous, drug-releasing implants for the treatment of opioid drug addiction. ( 28841773 )
2017
21
Drug Addiction and Histone Code Alterations. ( 28523544 )
2017
22
The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis. ( 28831923 )
2017
23
NADPH Oxidase Isoform 2 (NOX2) Is Involved in Drug Addiction Vulnerability in Progeny Developmentally Exposed to Ethanol. ( 28659754 )
2017
24
Understanding the Subjective Experience of Medication Adherence for Older Urban African Americans With Type 2 Diabetes and a History of Illicit Drug Addiction. ( 26965082 )
2016
25
The Therapeutic Utility of Employment in Treating Drug Addiction: Science to Application. ( 27777966 )
2016
26
"Not just eliminating the mosquito but draining the swamp": A critical geopolitics of Turkish Monitoring Center for Drugs and Drug Addiction and Turkey's approach to illicit drugs. ( 27267659 )
2016
27
Dopamine D4 receptor stimulation prevents nigrostriatal dopamine pathway activation by morphine: relevance for drug addiction. ( 27212105 )
2016
28
Fischer 344 and Lewis Rat Strains as a Model of Genetic Vulnerability to Drug Addiction. ( 26903787 )
2016
29
Lived Time Disturbances of Drug Addiction Therapy Newcomers. A Qualitative, Field Phenomenology Case Study at Monar-Markot Center in Poland. ( 27942253 )
2016
30
Psychiatric comorbidity in a sample of cocaine-dependent outpatients seen in the Community of Madrid drug addiction care network. ( 26990385 )
2016
31
CYP gene family variants as potential protective factors in drug addiction in Han Chinese. ( 27257124 )
2016
32
Construct Validity of Symptom Checklist-90-Revised (SCL-90-R) and General Health Questionnaire-28 (GHQ-28) in Patients with Drug Addiction and Diabetes, and Normal Population. ( 27252914 )
2016
33
Drug addiction: An affective-cognitive disorder in need of a cure. ( 27095547 )
2016
34
A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective. ( 27055610 )
2016
35
The potential biomarkers of drug addiction: proteomic and metabolomics challenges. ( 27328859 )
2016
36
Autism Spectrum Disorders and Drug Addiction: Common Pathways, Common Molecules, Distinct Disorders? ( 26903789 )
2016
37
Attention deficit-hyperactivity disorder in patients in rehabilitation of drug addiction. ( 27991991 )
2016
38
Pain Control in the Presence of Drug Addiction. ( 27068665 )
2016
39
Editorial: Exploring Gender and Sex Differences in Behavioral Dyscontrol: From Drug Addiction to Impulse Control Disorders. ( 26941657 )
2016
40
Caenorhabditis elegans as a Model to Study the Molecular and Genetic Mechanisms of Drug Addiction. ( 26810004 )
2016
41
Genetic polymorphisms in ALDH2 are associated with drug addiction in a Chinese Han population. ( 28052001 )
2016
42
Sex differences in impulsive and compulsive behaviors: a focus on drug addiction. ( 26935237 )
2016
43
Pre-incarceration police harassment, drug addiction and HIV risk behaviours among prisoners in Kyrgyzstan and Azerbaijan: results from a nationally representative cross-sectional study. ( 27435715 )
2016
44
A significant association between BDNF promoter methylation and the risk of drug addiction. ( 26976342 )
2016
45
Heantos-4, a natural plant extract used in the treatment of drug addiction, modulates T-type calcium channels and thalamocortical burst-firing. ( 27919294 )
2016
46
Drug Addiction: A Global Challenge. ( 27377484 )
2016
47
Self-deception as a mechanism for the maintenance of drug addiction. ( 26820418 )
2016
48
Targeting the ecology within: The role of the gut-brain axis and human microbiota in drug addiction. ( 27372861 )
2016
49
Similarity and Difference in Drug Addiction Process Between Heroin- and Methamphetamine-Dependent Users. ( 28001458 )
2016
50
RELATIONSHIP OF ASSESS SELF-ESTEEM AND LOCUS OF CONTROL WITH QUALITY OF LIFE DURING TREATMENT STAGES IN PATIENTS REFERRING TO DRUG ADDICTION REHABILITATION CENTERS. ( 27698598 )
2016

Variations for Drug Addiction

ClinVar genetic disease variations for Drug Addiction:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 FAAH NM_001441.2(FAAH): c.385C> A (p.Pro129Thr) single nucleotide variant risk factor rs324420 GRCh37 Chromosome 1, 46870761: 46870761

Expression for Drug Addiction

Search GEO for disease gene expression data for Drug Addiction.

Pathways for Drug Addiction

Pathways related to Drug Addiction according to GeneCards Suite gene sharing:

(show all 47)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.53 DRD1 DRD2 DRD4 MAP2K1 MAP2K2
2
Show member pathways
12.28 CREB1 MAP2K1 MAP2K2
3
Show member pathways
12.25 CREB1 MAP2K1 MAP2K2
4
Show member pathways
12.24 CREB1 MAP2K1 MAP2K2
5
Show member pathways
12.23 CREB1 MAP2K1 MAP2K2
6
Show member pathways
12.22 CREB1 MAP2K1 MAP2K2
7
Show member pathways
12.22 DRD1 DRD2 MAP2K1 MAP2K2
8
Show member pathways
12.2 CREB1 MAP2K1 MAP2K2
9
Show member pathways
12.17 CREB1 MAP2K1 MAP2K2
10 12.17 CREB1 DRD1 DRD2 DRD4
11
Show member pathways
12.16 CREB1 MAP2K1 MAP2K2
12
Show member pathways
12.16 CREB1 MAP2K1 MAP2K2
13
Show member pathways
12.12 CREB1 DRD1 MAP2K1 MAP2K2
14
Show member pathways
12.1 COMT CREB1 DRD1 DRD2 DRD4 MAP2K1
16
Show member pathways
12.03 CREB1 MAP2K1 MAP2K2
17
Show member pathways
12.03 CREB1 MAP2K1 MAP2K2
18 12.01 CREB1 MAP2K1 MAP2K2
19
Show member pathways
11.96 CREB1 MAP2K1 MAP2K2
20 11.92 CREB1 MAP2K1 MAP2K2
21
Show member pathways
11.86 CREB1 DRD1 DRD2 MAP2K1 MAP2K2
22
Show member pathways
11.85 CREB1 MAP2K1 MAP2K2
23
Show member pathways
11.8 DRD1 DRD2 DRD4
24 11.74 CREB1 MAP2K1 MAP2K2
25
Show member pathways
11.74 CREB1 DRD1 DRD2 GPSM1
26 11.72 CREB1 MAP2K1 MAP2K2
27 11.64 CREB1 MAP2K1 MAP2K2
28 11.34 MAP2K1 MAP2K2
29
Show member pathways
11.34 MAP2K1 MAP2K2
30 11.34 MAP2K1 MAP2K2
31
Show member pathways
11.33 CREB1 DRD1 DRD2 DRD4 MAP2K1 MAP2K2
32
Show member pathways
11.32 MAP2K1 MAP2K2
33 11.28 CREB1 MAP2K1 MAP2K2
34 11.22 MAP2K1 MAP2K2
35 11.2 CREB1 MAP2K1
36 11.2 MAP2K1 MAP2K2
37
Show member pathways
11.15 CREB1 MAP2K1
38 11.1 CREB1 MAP2K1 MAP2K2
39 11.09 MAP2K1 MAP2K2
40 11.03 DRD1 DRD2
41 11 CREB1 MAP2K1
42 10.98 MAP2K1 MAP2K2
43 10.94 MAP2K1 MAP2K2
44 10.91 MAP2K1 MAP2K2
45 10.85 MAP2K1 MAP2K2
46 10.78 CREB1 MAP2K1 MAP2K2
47 10.69 CREB1 MAP2K1 MAP2K2

GO Terms for Drug Addiction

Cellular components related to Drug Addiction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 non-motile cilium GO:0097730 8.62 DRD1 DRD2

Biological processes related to Drug Addiction according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.84 CREB1 MAP2K1 MAP2K2
2 response to drug GO:0042493 9.84 COMT CREB1 DRD1 DRD2
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 DRD2 MAP2K1 MAP2K2
4 activation of MAPK activity GO:0000187 9.76 DRD4 MAP2K1 MAP2K2
5 feeding behavior GO:0007631 9.69 DRD1 DRD2
6 positive regulation of protein serine/threonine kinase activity GO:0071902 9.68 MAP2K1 MAP2K2
7 response to nicotine GO:0035094 9.68 CREB1 DRD2
8 response to cocaine GO:0042220 9.68 DRD1 DRD2
9 positive regulation of multicellular organism growth GO:0040018 9.68 CREB1 DRD2
10 negative regulation of adenylate cyclase activity GO:0007194 9.67 DRD2 DRD4
11 adult walking behavior GO:0007628 9.67 DRD1 DRD2
12 behavioral fear response GO:0001662 9.67 DRD1 DRD4
13 ERK1 and ERK2 cascade GO:0070371 9.66 MAP2K1 MAP2K2
14 associative learning GO:0008306 9.65 DRD1 DRD2
15 arachidonic acid secretion GO:0050482 9.65 DRD2 DRD4
16 temperature homeostasis GO:0001659 9.64 DRD1 DRD2
17 synaptic transmission, dopaminergic GO:0001963 9.64 DRD1 DRD2
18 negative regulation of protein secretion GO:0050709 9.63 DRD2 DRD4
19 positive regulation of long-term synaptic potentiation GO:1900273 9.63 CREB1 DRD2
20 behavioral response to ethanol GO:0048149 9.62 DRD2 DRD4
21 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.62 DRD1 DRD2
22 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 DRD2 DRD4
23 grooming behavior GO:0007625 9.61 DRD1 DRD2
24 prepulse inhibition GO:0060134 9.6 DRD1 DRD2
25 striatum development GO:0021756 9.59 DRD1 DRD2
26 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD4
27 visual learning GO:0008542 9.58 CREB1 DRD1 DRD2
28 peristalsis GO:0030432 9.57 DRD1 DRD2
29 regulation of dopamine metabolic process GO:0042053 9.56 DRD1 DRD4
30 regulation of stress-activated MAPK cascade GO:0032872 9.55 MAP2K1 MAP2K2
31 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 MAP2K1 MAP2K2
32 regulation of early endosome to late endosome transport GO:2000641 9.51 MAP2K1 MAP2K2
33 proteolysis in other organism GO:0035897 9.49 MAP2K1 MAP2K2
34 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.48 DRD1 DRD2
35 cerebral cortex GABAergic interneuron migration GO:0021853 9.46 DRD1 DRD2
36 regulation of Golgi inheritance GO:0090170 9.43 MAP2K1 MAP2K2
37 response to amphetamine GO:0001975 9.43 DRD1 DRD2 DRD4
38 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.37 DRD2 DRD4
39 behavioral response to cocaine GO:0048148 9.33 DRD1 DRD2 DRD4
40 response to histamine GO:0034776 9.32 DRD2 DRD4
41 dopamine receptor signaling pathway GO:0007212 9.13 DRD1 DRD2 DRD4
42 dopamine metabolic process GO:0042417 8.92 COMT DRD1 DRD2 DRD4

Molecular functions related to Drug Addiction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein serine/threonine/tyrosine kinase activity GO:0004712 9.37 MAP2K1 MAP2K2
2 protein serine/threonine kinase activator activity GO:0043539 9.32 MAP2K1 MAP2K2
3 MAP kinase kinase activity GO:0004708 9.26 MAP2K1 MAP2K2
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.16 DRD2 DRD4
5 dopamine binding GO:0035240 9.13 DRD1 DRD2 DRD4
6 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD1 DRD2 DRD4

Sources for Drug Addiction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....